Scott is a senior graduate student in the Genetics Department of the Geisel School of Medicine. In the Cole Lab, his research is focused around understanding how small genetic changes (through somatic point mutations or inherited single nucleotide polymorphisms, SNPs) effect the transcription, expression, and function of two powerful oncogenes, c-Myc and c-Myb, ultimately gaining insight into their roles in the etiology and progression of hematopoietic cancers. Prior to joining the Cole Lab, Scott gained valuable professional experience by holding a variety of positions in the biotechnology industry. He committed to furthering his scientific education at Dartmouth's Geisel School of Medicine while a Senior Associate for a biotech start-up, Acceleron Pharma, in Cambridge, MA. At API he worked hand in hand senior management to develop powerful therapies against bone loss and muscle wasting disorders associated with Duchenne's Muscular Dystrophy (DMD) primarily through controlling TGFbeta-like signaling cascades. In the future Scott would like to utilize his varied academic and professional experiences to educate policy makers on the importance of governmental support for ground breaking scientific research and treatment of chronic disease. When not in lab, Scott enjoys drinking copious amounts of good coffee, practicing his amazing dance moves, waking up on a sailboat, and spending as much time as he can with his amazing wife.